Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele.
Aged
Chromosomes, Human, Pair 11
/ genetics
Chromosomes, Human, Pair 14
/ genetics
Chromosomes, Human, Pair 4
/ genetics
Female
Humans
Immunoglobulin Heavy Chains
/ genetics
Immunoglobulin lambda-Chains
Leukemia, Plasma Cell
/ genetics
Loss of Heterozygosity
Male
Middle Aged
Neoplasm Proteins
/ genetics
Translocation, Genetic
Allelic exclusion
Bence Jones protein
Chromosomal translocation
Class switch recombination
Immunoglobulin heavy-chain
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
14
01
2019
accepted:
11
03
2019
revised:
09
03
2019
pubmed:
20
3
2019
medline:
3
5
2019
entrez:
20
3
2019
Statut:
ppublish
Résumé
Light-chain plasma cell myeloma (LC-PCM) is a PCM subtype in which only immunoglobulin light-chain is secreted. However, the absence of immunoglobulin heavy-chain (IGH) production in this condition has not been fully elucidated. To address this issue, we retrospectively analyzed patients at our center with LC-PCM and found a group who had only split signals of IGH gene derived from 14q32/IGH translocations by fluorescence in situ hybridization (FISH). Six patients were identified with only split signals of the IGH gene derived from 14q32/IGH translocations. Five of these patients were newly diagnosed, while one had IgG-λ PCM at presentation, which transformed to λ LC-PCM after treatment. The translocation partners were identified in four patients: two cases of (11;14)(q13;q32) and two cases of (4;14)(p16;q32). The development of LC-PCM appears to be explained by the application of allelic exclusion in these patients, such that 14q32/IGH translocation in one allele contributes to the pathogenesis of PCM and the subsequent loss of the other allele is responsible for the loss of IGH production. These findings suggest that a FISH pattern of IGH with "split and loss" may constitute a unique subgroup of LC-PCM.
Identifiants
pubmed: 30887274
doi: 10.1007/s12185-019-02629-7
pii: 10.1007/s12185-019-02629-7
doi:
Substances chimiques
Immunoglobulin Heavy Chains
0
Immunoglobulin lambda-Chains
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-577Références
Br J Haematol. 1999 Apr;105(1):131-40
pubmed: 10233376
Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72
pubmed: 10626149
Blood. 2000 Aug 1;96(3):1087-93
pubmed: 10910926
Oncogene. 2001 Sep 10;20(40):5611-22
pubmed: 11607813
Cancer. 1975 Sep;36(3):842-54
pubmed: 1182674
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Blood. 2004 May 15;103(10):3869-75
pubmed: 14715636
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Blood. 2006 Sep 15;108(6):2013-9
pubmed: 16728700
Haematologica. 2007 Jan;92(1):143-4
pubmed: 17229655
J Cancer Res Clin Oncol. 2009 Mar;135(3):477-84
pubmed: 18802723
Immunol Rev. 2010 Sep;237(1):22-42
pubmed: 20727027
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Int J Hematol. 2013 Mar;97(3):313-23
pubmed: 23456262
Blood. 2014 May 29;123(22):3414-9
pubmed: 24733348
Int J Hematol. 2018 Mar;107(3):278-285
pubmed: 29368256
Blood. 1985 Feb;65(2):305-10
pubmed: 3967084
J Exp Med. 1965 Nov 1;122(5):853-76
pubmed: 4159057
CA Cancer J Clin. 1976 Mar-Apr;26(2):119-21
pubmed: 816431